Breo Ellipta Patent Expiration

BREO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7101866 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

USRE44874 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(1 year, 3 months ago)

US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5873360 GLAXO GRP LTD Inhalation device
Feb, 2016

(8 years ago)

US6759398 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US6537983 GLAXO GRP LTD Anti-inflammatory androstane derivatives
Aug, 2021

(2 years ago)

US7629335 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US6878698 GLAXO GRP LTD Anti-inflammatory androstane derivatives
Aug, 2021

(2 years ago)

US7101866 GLAXO GRP LTD Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US7776895 GLAXO GRP LTD Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(1 year, 10 months ago)

US7361787 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(1 year, 3 months ago)

US7439393

(Pediatric)

GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 4 months from now)

US8511304 GLAXO GRP LTD Medicament dispenser
Jun, 2027

(2 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8511304

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Dec, 2027

(3 years from now)

US8161968 GLAXO GRP LTD Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXO GRP LTD Counter for use with a medicament dispenser
Apr, 2028

(3 years from now)

US8161968

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Aug, 2028

(4 years from now)

US11116721 GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Feb, 2029

(4 years from now)

US11116721

(Pediatric)

GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Aug, 2029

(5 years from now)

US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXO GRP LTD Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser
Oct, 2030

(6 years from now)

US8746242

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2031

(6 years from now)



Breo Ellipta is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is used for the long-term maintenance treatment of airflow obstruction in patients with COPD and asthma, including chronic bronchitis and emphysema, to reduce exacerbations. Breo Ellipta uses Fluticasone Furoate; Vilanterol Trifenatate as an active ingredient. Breo Ellipta was launched by Glaxo Grp Ltd in 2023. It is is available in powder form for inhalation use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 11, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 30, 2018
New Indication(I-708) Apr 30, 2018
New Chemical Entity Exclusivity(NCE) May 10, 2018
M(M-202) May 15, 2020
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a his...

Dosage: POWDER

More Information on Dosage

BREO ELLIPTA family patents

Family Patents